Qualmedica Research, LLC | Owensboro, KY

Research site

Site insights

Top conditions

Top treatments


Parent organization

This site is a part of Qualmedica Research, LLC

Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 10 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Drug: Lasmiditan

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Drug: Placebo
Drug: Lasmiditan

The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment d...

Active, not recruiting
Attention Deficit Hyperactivity Disorder
Drug: Guanfacine hydrochloride (TAK-503)
Other: Placebo

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide
Locations recently updated

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Drug: Placebo
Drug: Tirzepatide

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

Lilly logo
Janssen (J&J Innovative Medicine) logo
Concert Pharmaceuticals logo
Pfizer logo
Shire logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems